Category Archives: Tms

ValuEngine lowered shares of Edap Tms (NASDAQ:EDAP) from a buy rating to a hold rating in a research report released on Saturday, August 31st, ValuEngine reports.

Other research analysts have also issued research reports about the stock. HC Wainwright set a $7.00 price target on shares of Edap Tms and gave the stock a buy rating in a research report on Tuesday, June 11th. TheStreet lowered shares of Edap Tms from a b- rating to a d+ rating in a report on Monday, June 17th. Finally, Zacks Investment Research raised shares of Edap Tms from a sell rating to a hold rating in a report on Tuesday, July 16th.

Shares of EDAP traded up $0.08 during trading hours on Friday, reaching $4.08. 119,357 shares of the company traded hands, compared to its average volume of 109,650. Edap Tms has a 1-year low of $1.35 and a 1-year high of $5.42. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.97 and a current ratio of 2.40. The stock has a market cap of $115.41 million, a P/E ratio of 204.00 and a beta of 1.87. The stocks fifty day moving average is $3.24 and its 200 day moving average is $3.37.

Edap Tms (NASDAQ:EDAP) last posted its quarterly earnings results on Wednesday, August 28th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters consensus estimate of $0.01 by $0.04. Edap Tms had a net margin of 4.57% and a return on equity of 23.31%. The firm had revenue of $14.04 million during the quarter, compared to analyst estimates of $11.92 million. On average, equities research analysts predict that Edap Tms will post 0.18 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fosun International Ltd grew its stake in shares of Edap Tms by 9.4% during the second quarter. Fosun International Ltd now owns 397,568 shares of the medical equipment providers stock valued at $1,145,000 after purchasing an additional 34,083 shares during the last quarter. Morgan Stanley boosted its stake in Edap Tms by 222.7% in the second quarter. Morgan Stanley now owns 267,408 shares of the medical equipment providers stock valued at $722,000 after acquiring an additional 184,539 shares during the last quarter. Acadian Asset Management LLC bought a new position in Edap Tms in the second quarter valued at approximately $607,000. Susquehanna International Group LLP boosted its stake in Edap Tms by 762.9% in the second quarter. Susquehanna International Group LLP now owns 205,178 shares of the medical equipment providers stock valued at $556,000 after acquiring an additional 181,401 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Edap Tms in the second quarter valued at approximately $282,000. 13.24% of the stock is currently owned by institutional investors and hedge funds.

Edap Tms Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Featured Story: Cryptocurrencies

To view ValuEngines full report, visit ValuEngines official website.

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post here:

Edap Tms (NASDAQ:EDAP) Downgraded to Hold at ValuEngine - TechNewsObserver

In its most recent trading session, EDAP TMS S.A. (EDAP) spiked up by 2.0% here is what that looked like (as of 2019-09-18):

Whats the reason for these moves? To understand this better, it is helpful to analyze some technical indicators. The most important ones are as follows:

A Money Flow Index (MFI) of 100.0, a Relative Strength Index (RSI) of 50.0, a True Strength Index (TSI) of 100.0, a Moving Average Convergence Divergence (MACD) of -0.002, an Average Directional Movement Index (ADX) of unknown, an Average True Range (ATR) of 0.143, an Accumulation/Distribution Index (ADI) of 0.143, an On-Balance Volume (OBV) of 180.129, and a Chaiikin Money Flow (CMF) of -4.04. 1.556

Now lets plug these indicators in. Consulting Trading View, putting it all together gets the following:

That is what an analysis of technical indicators seems to indicate for EDAP TMS S.A. (EDAP). And finally, make sure to DO YOUR OWN RESEARCH! Take the above with a grain of salt, and do your own research.

2335 Holt Street, SAINT CROIX IN 47576561-265-3129becky@merakhaber.com

Read more:

EDAP TMS SA (EDAP) Jumped Up 2.0%, But Why? - Merakhaber News

CLAREMONT, Calif., Aug. 23, 2017 /PRNewswire/ --Achieve TMS, the largest and most experienced provider of deep Transcranial Magnetic Stimulation (dTMS) for the treatment of depression, will open a state-of-the-art center in Claremont, CA on September 1. This new center will enable local residents and students to benefit from the powerful and highly effective impact of dTMS technology, which is approved by the FDA and covered by every major health insurance company in the U.S.

"With 1 in 6 Americans suffering fromdepressionthere is a huge need for treatments that are proven to make a difference in the battle against this debilitating disease," said Manish Sheth, MD, PhD. "Deep Transcranial Magnetic Stimulation (TMS) is known to be an effective tool in the battle. Patients and their families are looking for an effective way to move away from depression into a place where lives are productive, balanced, healthy and well integrated. TMSis a vital tool that helps facilitate healing. We look forward to partnering with psychiatrists, psychologists and therapists in the Claremont area to expand access to this treatment option."

Deep TMS works by administering magnetic pulses through an H-coil on the scalp that is targeted to the mood center of the brain. The magnetic fields induce electrical currents that stimulate underactive neurons, helping to reset brain chemistry, resulting in improved sleep, concentration and overall mood. It is safe, non-invasive and highly effective for those who are treatment resistant and/or have experienced no relief from medication.

In more than 60 clinical studies globally, dTMS has consistently demonstrated statistically significant response and remission rates. The therapy is well tolerated by patients, causing no adverse effects. Treatment sessions are prescribed 5 days per week for 4-6 weeks, with each session lasting 20 minutes. There is no sedation involved, and no down time.

The new Achieve TMS Center in Claremont is located at 1490 Claremont Blvd. Suite 203.

Achieve TMS welcomes inquiries about the dTMS treatment and is scheduling complimentary consultations and appointments for Claremont at this time.

For more information please contact Achieve TMS at (877) 391-7019 or visit http://www.achievetms.com.

For media inquiries, please contact:

Laura Segall, Chief Marketing Officer

760-533-2784

172840@email4pr.com

View original content with multimedia:http://www.prnewswire.com/news-releases/landmark-tms-provider--achieve-tms--opening-in-claremont-ca-300507785.html

SOURCE AchieveTMS

http://www.achievetms.com

Read this article:

Landmark TMS Provider - Achieve TMS - Opening in Claremont, CA - PR Newswire (press release)

August 24, 2017 16:20 ET | Source: EDAP TMS SA

LYON, France, August 24, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Marc Oczachowski, Chief Executive Officer, will present at the 19th Annual Rodman & Renshaw Global Investment Conference to be held September 10-12, 2017 at the Lotte New York Palace Hotel, New York, New York. EDAP-TMS' presentation will take place Monday, September 11th, 2017 at 3:00pm Eastern Time. A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at http://www.edap-tms.net. A replay of the conference presentation will also be available.

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. Ablatherm Fusion is not FDA cleared yet. The Company also markets an innovative robot-assisted HIFU device, the Focal One, dedicated to focal therapy of prostate cancer. Focal One is CE marked but is not FDA cleared. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visithttp://www.edap-tms.com, andhttp://www.hifu-prostate.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Investor Contact

CG CAPITAL Rich Cockrell 877.889.1972 investorrelations@cg.capital

Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.com

Vaulx-en-Velin, FRANCE

http://www.edap-tms.com

EDAP TMS SA Logo

LOGO URL | Copy the link below

Formats available:

Originally posted here:

EDAP TMS to Present at the 19th Annual Rodman & Renshaw Global Investment Conference - GlobeNewswire (press release)

August 23, 2017 16:01 ET | Source: EDAP TMS SA

EDAP-TMS Reports Record Second Quarter and First Half 2017 Results

LYON, France, August 23, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today financial results for the second quarter ended June 30, 2017, and provided an update on strategic and operational accomplishments.

"We are incredibly pleased to announce record second quarter revenue of 9.3 million", said Marc Oczachowski, EDAP's Chief Executive Officer. "Additionally, the 25% growth in HIFU revenues compared to the first quarter of 2017 shows a significant return from our increased sales and marketing efforts. We also submitted our 510(k) filing to the FDA for our novel Ablatherm Fusion device recently, and are working to file a new 510(k) application with the FDA for the Focal One device in the U.S. The addition of these HIFU devices to our U.S. marketing efforts, coupled with the active C-Code, should serve to help our customers service the widest possible range of patients."

Second Quarter 2017 Results

Total revenue for the second quarter 2017 was EUR 9.3 million (USD 10.4 million), compared to EUR 8.2 million (USD 9.2 million) for the second quarter of 2016, a 13.7% increase and the highest second quarter revenue in EDAP's history.

For the three months ended June 30, 2017, total revenue for the Lithotripsy division was EUR 6.4 million (USD 7.2 million), a 33.9% increase compared to EUR 4.8 million (USD 5.4 million) during the year-ago period. During the second quarter of 2017, EDAP sold 7 lithotripsy devices compared to 6 lithotripsy devices sold during the second quarter of 2016.

Total revenue in the HIFU business for the second quarter was EUR 2.9 million (USD 3.2 million) compared to EUR 3.4 million (USD 3.8 million) for the second quarter of 2016. During the second quarter of 2017, EDAP sold 1 Focal One and 2 Ablatherm HIFU devices compared to 1 Focal One and 3 Ablatherm devices during the second quarter of 2016.

Gross profit for the second quarter 2017 was EUR 4.0 million (USD 4.5 million), compared to EUR 3.5 million (USD 3.9 million) for the year-ago period. Gross profit margin on net sales expanded to 43.2% in the second quarter of 2017, compared to 42.2% in the prior year period, primarily due to increase in revenues.

Operating expenses for the second quarter of 2017 totaled EUR 4.4 million (USD 5.0 million) for the second quarter of 2017, compared to EUR 3.8 million (USD 4.3 million) for the same period in 2016. The increase reflects increased sales and marketing efforts associated with the expansion of the HIFU and UDS businesses.

Operating loss for the second quarter of 2017 was EUR 0.4 million (USD 0.5 million), compared to an operating loss of EUR 0.3 million (USD 0.4 million) in the second quarter of 2016.

Net loss for the second quarter of 2017 was EUR 1.7 million (USD 2.0 million), or loss of EUR 0.06 per diluted share, as compared to net income of EUR 2.5 million (USD 2.8 million), or earnings of EUR 0.09 per diluted share in the year-ago period. Net loss during the second quarter of 2017 included a non-cash interest expense of EUR 0.6 million (USD $0.6 million) to adjust the accounting fair value of the outstanding warrants.

First Six Months 2017 Results

Total revenue for the first half of 2017 was EUR 18.0 million (USD 19.7 million) - a new record level for the period, up 6.3% compared to EUR 16.9 million (USD 18.8 million) for the first half of 2016. For the six months ended June 30, 2017, total revenue for the Lithotripsy division was EUR 12.8 million (USD 14.0 million), an increase of 24.6% when compared to EUR 10.2 million (USD 11.4 million), during the year ago period. This increase was driven by growth in both the distribution business and lithotripsy device sales.

Total revenue in the HIFU division for the first six months 2017 was EUR 5.2 million (USD 5.7 million) compared to EUR 6.7 million (USD 7.4 million) for the six months ended June 30, 2016. This decrease was primarily due to slow U.S. sales of HIFU devices during the first half of the year, tempered by an increase in HIFU treatment driven revenues.

Gross profit for the first half of 2017 was EUR 7.6 million (USD 8.3 million) and gross profit margin was 42.1%, compared to 45.8% in the year ago period. The contraction in gross profit margin was primarily due to an unfavorable mix of HIFU and UDS segment revenues.

The Company recorded an operating loss for the first half of 2017 of EUR 0.8 million (USD 0.9 million), compared with an operating profit of EUR 0.4 million (USD 0.4 million) in the first six months of 2016.

Net loss for the first half of 2017 was EUR 0.1 million (USD 0.1 million), or EUR 0.00 per diluted share, as compared to a net income of EUR 3.9 million (USD 4.3 million), or EUR 0.14 per diluted share, in the first half of 2016. Net income for the first six months of 2017 included non-cash interest income of EUR 1.4 million (USD 1.5 million) to adjust the accounting fair value of the outstanding warrants

At June 30, 2017, cash and cash equivalents, including short-term treasury investments, were EUR 18.6 million (USD 21.2 million).

Conference Call

An accompanying conference call will be conducted by Philippe Chauveau, Chairman of the Board, Marc Oczachowski, Chief Executive Officer; and Francois Dietsch, Chief Financial Officer, to go over the results. The call will be held at 9:00 AM ET, on Thursday, August 24, 2017. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Date:Thursday, August 24, 2017, 9:00 AM ET Conference dial-in:877-269-7756 International dial-in:201-689-7817 Conference Call Name:EDAP-TMS Second Quarter 2017 Results Conference Call Webcast Registration:Click Here

Following the live call, a replay will be available on the Company's website, http://www.edap-tms.com under "Investors Information."

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. Ablatherm Fusion is not FDA cleared yet. The Company also markets an innovative robot-assisted HIFU device, the Focal One, dedicated to focal therapy of prostate cancer. Focal One is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, andhttp://www.hifu-planet.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

EDAP TMS S.A. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands of Euros and U.S. Dollars, except per share data)

Three Months Ended: Three Months Ended:

Net sales of RPP and Leases

1,304

1,316

1,458

1,474

2,037

1,611

NOTE: Translated for convenience of the reader to U.S. dollars at the 2017 average three months' noon buying rate of 1 Euro = 1.1181USD, and 2016 average three months' noon buying rate of 1 Euro = 1.1203 USD.

EDAP TMS S.A. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands of Euros and U.S. Dollars, except per share data)

Six Months Ended: Six Months Ended:

Net sales of RPP and leases

2,599

2,578

2,844

2,865

3,879

3,078

4,244

3,421

NOTE: Translated for convenience of the reader to U.S. dollars at the 2017 average six months' noon buying rate of 1 Euro = 1.0942USD, and 2016 average six months' noon buying rate of 1 Euro = 1. 1116 USD.

EDAP TMS S.A. CONSOLIDATED BALANCE SHEETS HIGHLIGHTS (Amounts in thousands of Euros and U.S. Dollars)

NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.1412 USD, on June 30, 2017 and at the noon buying rate of 1 Euro = 1.0697 USD, on March 31, 2017.

EDAP TMS S.A. CONDENSED STATEMENTS OF OPERATIONS BY DIVISION SIX MONTHS ENDED JUNE 30, 2017 (Amounts in thousands of Euros)

HIFU Division

UDS Division

Corporate

Sales of goods

2,626

8,852

11,478

Research & Development

(1,211)

OPERATING PROFIT (LOSS)

(884)

804

(768)

(847)

Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 bconfort@edap-tms.com

Investors Rich Cockrell CG CAPITAL 877.889.1972 investorrelations@cg.capital

More here:

EDAP TMS Reports Record Second Quarter and First Half 2017 Results - GlobeNewswire (press release)

Edap Tms SA (EDAP) shares have seen their Schaff Trend Cycle gradually downtrendthis week over the past fewsessions. While this indicates negativeprice momentum, it also suggests that if the reading moves into oversold territory (STC of 30), thenthe liklihood of a reversal greatly increases. Investors will be watching very closely over the next few days to see if the trend contiunes or reverses.

The Schaff Trend Cycle (STC) indicator combines the common indicators of MACD & Stochastic. The benefit of the Schaff Trend Cycle is that it is meant to be quicker than the standard macd and stochastic signals. The indicator uses similar methods to a MACD i.e uses exponetial moving averages but applies a cycle factor to them. Then the price is smoothed using a mofidied Wilders smoothing algorithm. The Schaff Trend Cycle indicator fluctuates between 0 and 100. Readings below 20 are considered oversold while readings above 80 are considered overbought. The STCindicator fluctuates between 0 and 100. Readings below 20 are considered oversold while readings above 80 are considered overbought.

Active investors are typically interested in the factors that drive stock price movements. Buying an individual stock means that you own a piece of the company. The hope is that the company does very well and becomes highly profitable. A profitable company may decide to do various things with the profits. They may reinvest profits back into the business, or they may choose to pay shareholders dividends from those earnings. Sometimes stocks may eventually become undervalued or overvalued. Spotting these trends may lead to further examination or the underlying fundamentals of the company. A company that continues to disappoint on the earnings front may have some issues that need to be addressed. It is highly important to make sure all the research is done on a stock, especially if the investor is heavily weighted on the name. Sometimes earnings reports may be good, but the stock price does not reflect that. Having a good understanding of the entire picture may help investors better travel the winding stock market road.

Checking on some other popular technical levels, Edap Tms SA (EDAP) has a 14-day Commodity Channel Index (CCI) of -17.91. The CCI technical indicator can be employed to help figure out if a stock is entering overbought or oversold territory. CCI may also be used to help discover divergences that may signal reversal moves. A CCI closer to +100 may provide an overbought signal, and a CCI near -100 may provide an oversold signal.

Tracking other technical indicators, the 14-day RSI is presently standing at 37.05, the 7-day sits at 37.85, and the 3-day is resting at 41.71 for Edap Tms SA (EDAP). The Relative Strength Index (RSI) is a highly popular technical indicator. The RSI is computed base on the speed and direction of a stocks price movement. The RSI is considered to be an internal strength indicator, not to be confused with relative strength which is compared to other stocks and indices. The RSI value will always move between 0 and 100. One of the most popular time frames using RSI is the 14-day.

Moving averages have the ability to be used as a powerful indicator for technical stock analysis. Following multiple time frames using moving averages can help investors figure out where the stock has been and help determine where it may be possibly going. The simple moving average is a mathematical calculation that takes the average price (mean) for a given amount of time. Currently, the 7-day moving average is sitting at 2.67.

Lets take a further look at the Average Directional Index or ADX. The ADX measures the strength or weakness of a particular trend. Investors and traders may be looking to figure out if a stock is trending before employing a specific trading strategy. The ADX is typically used along with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) which point to the direction of the trend. The 14-day ADX for Edap Tms SA (EDAP) is currently at 23.41. In general, and ADX value from 0-25 would represent an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would signify a very strong trend, and a value of 75-100 would point to an extremely strong trend.

Follow this link:

What is the Schaff Indicator Suggesting For Edap Tms SA (EDAP)? - Morgan Research

To celebrate TMSs 60th birthday, a match is being played (and commentated upon) in Leeds. Agnews team will take on Geoffrey Boycotts; with the two broadcasting greats represented by their respective on-field captains Phil Tufnell and Vaughan. I think I may have drawn the short straw with my captain, Agnew said with a smile.

TMS favourites will play, as well as celebrities including Jim Carter of Downton Abbey, sprinter Yohan Blake and McFly drummer Harry Judd (a good cricketer, according to Agnew).

They could have sold 10 times the tickets, Agnew said. The TMS mystique remains strong.

It is amazing how much this programme continues to appeal, Agnew said.

Our audience numbers go up and up.

It is a companion for people: most are listening in a confined space, car, headphones in the office, in bed. Often for seven hours a day, five days at a time. There is a feeling of camaraderie, that we are in it together.

For many, TMS has been there during good times and bad. Agnew himself experienced this recently.

My wife Emma has been diagnosed with breast cancer, he said. Because of the nature of the relationship we have with listeners, if I am not on it, people will ask wheres Aggers?

Originally posted here:

Like most families, Test Match Special has had some bitter rows - Telegraph.co.uk

August 16, 2017

Fleets using TMW Systems Innovative IES, Access, or AccessPlus transportation management solutions can now extend real-time order and shipping information to their customers with the IES Freight Tracker portal, an integrated customer service and dispatch.

Replacing TMWs Pressurize platforms, the new visibility portal enables carriers to improve customer satisfaction through accurate, transparent and timely order updates.

More than ever before, transportation and logistics providers are facing pressure to provide customers with transparency into every step of the delivery process, said Ray West, senior vice president and general manager of TMS solutions for TMW. With the launch of the IES Freight Tracker portal, we are enabling Innovative IES users to meet these heightened expectations by giving them a way to provide customers with accurate, up-to-date load status whenever and wherever they want to access them.

The IES Freight Tracker portal is designed to be a scalable and cost-effective customer support tool that integrates into a users existing Innovative IES platform. The web-based solution allows carriers to view shipments from multiple customer codes and utilize drag-and-drop functionality to reposition shipment details.

Users can offer their customers configurable, secure access to real-time delivery details. Transportation providers can easily customize settings for each customer, allowing them to view orders based on type and to sort and filter shipment details. In addition, customers can use the portal to access shipment documents and related images, export shipment data to Excel, and create up to seven hyperlinks to important documents indexed by order number.

Implementation of the IES Freight Tracker portal requires the use of Innovative IES, Access, or Access Plus solutions in version R9.7 or later along with the Innovative Web Edition module. Other requirements include an internet-connected device with a web browser and business-quality internet bandwidth.

The rest is here:

TMW Adds Real-Time Freight Tracking to TMS Solutions - TopNews ... - Heavy Duty Trucking

Texas Motor Speedway will celebrate the first total solar eclipse across the continental United States in 38 years with a watch party on the world's largest TV as well as a celestial-themed, pre-event luncheon for its entire staff.

Texas Motor Speedway President Eddie Gossage is throwing a solar eclipse bash in the speedway infield beginning at 12:30 p.m. CT Monday for his entire staff of more than 80 employees that will feature a variety of celestial-named delights. The staff will enjoy "Out Of This World" Dickey's BBQ sandwiches, Krispy Kreme limited-edition Solar Eclipse doughnuts, Moon Pies and Sun Chips among the treats for lunch at the Fuzzy's Taco Shop in the infield.

The speedway also has produced "No Limits" Solar Eclipse t-shirts and celestial snack packs that will be raffled off to the staff through solar eclipse trivia games at lunch. The packs consist of a Moon Pie, Eclipse Gum, Star Crunch, Cosmic Brownie, Milky Way, Starburst, Sun Chips and Satellite Wafers.

Each staff member also will receive Eclipse Shades for the option to watch the eclipse directly in addition to viewing it on Big Hoss TV with no special glasses needed. North Texas will see a partial solar eclipse - the moon will cover 76 percent of the sun's surface in Dallas/Fort Worth - with maximum viewing coming at 1:09 p.m.

While Texas Motor Speedway couldn't provide those highly sought-after Eclipse Shades from Denton's Orbit Press for the general public, the speedway will film the eclipse with a special camera filter from the grandstand rooftop and air it live of Big Hoss TV and Facebook Live.

Locally, Texas Motor Speedway will open its infield to the public to watch the eclipse on the colossal "Big Hoss TV" that stands 12 stories tall on the speedway's backstretch. "Big Hoss" is nearly 23,000 square feet of high-definition screen display that boasts 281 trillion colors and five million pixels. The Guinness Book of World Records recognized "Big Hoss" as the world's largest HDTV in 2014.

For those visiting, the South Infield Tunnel will be open to the public beginning at Noon CT. Parking will be available in the infield camping area in front of "Big Hoss" (Turns 2 & 3 side of the infield). Visitors can watch from the comfort of their vehicle or are encouraged to bring lawn chairs to watch from outside. The South Paddock concession restrooms also will be open.

For Texas Motor Speedway and solar eclipse fans across the state, country and the world, the speedway also will utilize Facebook Live on the speedway's page to broadcast the eclipse in North Texas beginning at 11:35 a.m.

TMS PR

More here:

TMS To Host Solar Eclipse Watch Party on World's Largest TV - Speedway Digest (press release) (blog)

EDAP TMS S.A. (NASDAQ:EDAP)s share price has changed -0.37% after the completion of a recent trading day,touching$2.68 while generating interest from penny stock investors.

The commodity is -9.85% away from the 20-Day Simple Moving Average. Their 50-Day Simple Moving Average is a difference of -16.04% from the current levels. Moving further back, the 200-Day Simple Moving Average is a -10.13% difference from todays price. As it stands today, the stock is -30.39% from its 50-Day High and 0.75% from the 50-day low.

EDAP TMS S.A. (NASDAQ:EDAP)s performance this year to date is -18.29%. The stock has performed -0.74% over the last seven days, -14.92% over the last thirty, and -4.29% over the last three months. Over the last six months, EDAP TMS S.A.s stock has been -13.55% and -11.55% for the year.

Investing in penny stocks can be one of the riskier behaviors that traders and investors engage in within the stock market. Penny stocks are defined as stocks with a share price below a certain amount, usually under $1 per share. Beginners find these stocks to be attractive due to their low price, but penny stocks come with more volatility and risk than the more traditional blue chip stocks.

If youre thinking about investing in penny stocks, you need to understand the inherent risks involved before wagering significant amounts of money in the market. Penny stocks arent necessarily traded on a major stock exchange, meaning they dont have to file with the SEC, and arent publicly scrutinized, i.e., penny stocks are bets without a much information.

Most of the time there is no minimum standard that a penny stocks has to fulfill in order to remain on the Over-the-Counter Bulletin Board (OTCBB) exchange. Because of this, the added safety bubble isnt there between sellers and investors.

Often times finding a buyer for penny stocks can prove to be difficult. If a buyer cant be found, a seller may have to lower the asking price, sometimes to the point where its no longer profitable to sell, making it a losing proposition.

Having an account with an online brokerage account is key, you need to have a straightforward way to make transactions. Online brokerage accounts allow easy access to stocks and feature low commissions and minimal fees. Its important to make sure that your online brokerage account provides for you the information that you need to help you make the best decisions. The best brokerage accounts include charts, historic data and the like.

Understand the trade status for whatever penny stocks you might be interested in. Experts point out that penny stocks usually have share prices because of specific reasons. There are certain warning signs inherent in the riskier penny stocks. Make sure that penny stocks youve considered are traded over a regular market exchange and not just over-the-counter. Over-the-counter (OTC) stock listings dont require the same stringent regulation that larger stocks do, creating additional risk.

Penny stocks are a breeding ground for fraudsters and unscrupulous types, looking for an easy mark. Fraudsters can make easy money is by investing large in a stock, hyping it up using questionable business practices, and then finding gullible buyers willing to take it off their hands. This nebulous strategy is called the pump-and-dump.

Disclaimer:The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs. Where quoted, past performance is not indicative of future performance.

See the rest here:

Investors Focusing the Lens on Shares of EDAP TMS SA (NASDAQ:EDAP) - Nelson Research